Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Annalisa Chiappella, Alessia Castellino, Maura Nicolosi, Elisa Santambrogio & Umberto Vitolo. (2017) Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives. Expert Review of Hematology 10:4, pages 289-297.
Read now
Read now
Annalisa Arcari, Annalisa Chiappella, Michele Spina, Luca Zanlari, Patrizia Bernuzzi, Vanessa Valenti, Monica Tani, Roberto Marasca, Maria Giuseppina Cabras, Renato Zambello, Alberto Santagostino, Fiorella Ilariucci, Giuseppe Carli, Pellegrino Musto, Paolo Savini, Dario Marino, Francesco Ghio, Massimo Gentile, Maria Christina Cox & Daniele Vallisa. (2016) Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leukemia & Lymphoma 57:8, pages 1823-1830.
Read now
Read now
Concepción Fernández-Rodríguez, Antonio Salar, Alfons Navarro, Eva Gimeno, Silvia Pairet, Laura Camacho, Mariana Ferraro, Sergi Serrano, Carles Besses, Beatriz Bellosillo & Blanca Sanchez-Gonzalez. (2016) Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells. Leukemia & Lymphoma 57:3, pages 692-699.
Read now
Read now
Enrico Derenzini, Pier Luigi Zinzani & Bruce D. Cheson. (2014) Bendamustine: role and evidence in lymphoma therapy, an overview. Leukemia & Lymphoma 55:7, pages 1471-1478.
Read now
Read now
Karin Boslooper, Robby Kibbelaar, Huib Storm, Nic J. G. M. Veeger, Sjoerd Hovenga, Gerhard Woolthuis, Bas van Rees, Elly de Graaf, Eric van Roon, Hanneke C. Kluin-Nelemans, Peter Joosten & Mels Hoogendoorn. (2014) Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leukemia & Lymphoma 55:3, pages 526-532.
Read now
Read now
Hervé Ghesquières, Aspasia Stamatoullas, Olivier Casasnovas, Franck Morschhauser, Emmanuel Gyan, Jean Gabarre, Marion Malphettes, Laurence Clément, Céline Ferlay & Pauline Brice. (2013) Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leukemia & Lymphoma 54:11, pages 2399-2404.
Read now
Read now
Articles from other publishers (18)
Friederike Braulke, Florian Zettl, Marita Ziepert, Andreas Viardot, Christoph Kahl, Gabriele Prange-Krex, Agnieszka Korfel, Martin Dreyling, Alexander Bott, Ulrich Wedding, Dietmar Reichert, Maike de Wit, Frank Hartmann, Viola Poeschel, Norbert Schmitz, Mathias Witzens-Harig, Wolfram Klapper, Andreas Rosenwald, Gerald Wulf, Bettina Altmann & Lorenz Trümper. (2022) First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial. HemaSphere 6:12, pages e808.
Crossref
Crossref
Vicki A. Morrison. 2020. Geriatric Oncology. Geriatric Oncology
583
612
.
Roosa Enni Inkeri Prusila, Pekka Peroja, Esa Jantunen, Taina Turpeenniemi‐Hujanen & Outi Kuittinen. (2019) Treatment of diffuse large B‐cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP‐16). Hematological Oncology 37:2, pages 136-142.
Crossref
Crossref
Roland Christian Schelker, Wolfgang Herr, Albrecht Reichle & Martin Vogelhuber. (2018) Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience. BMC Cancer 18:1.
Crossref
Crossref
Chieh-Lung Cheng, Jia-Hau Liu, Sheng-Chieh Chou, Ming Yao, Jih-Luh Tang & Hwei-Fang Tien. (2018) Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. European Journal of Haematology 101:1, pages 28-37.
Crossref
Crossref
Vicki A. Morrison. 2018. Geriatric Oncology. Geriatric Oncology
1
31
.
Sih-Han Liao, Yin-Kai Chen, Shan-Chi Yu, Ming-Shiang Wu, Hsiu-Po Wang & Ping-Huei Tseng. (2017) An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review. SAGE Open Medical Case Reports 5, pages 2050313X1770919.
Crossref
Crossref
Taha Alrifai, Kelly Grant Szymanski, Parameswaran Venugopal, Brett Mahon, Tochukwu Okwuosa & Reem Karmali. (2017) Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20%. Chemotherapy 62:2, pages 140-146.
Crossref
Crossref
Steven I. Park, Natalie S. Grover, Oludamilola Olajide, Adam S. Asch, James G. Wall, Kristy L. Richards, Anna L. Sobol, Allison M. Deal, Anastasia Ivanova, Matthew C. Foster, Hyman B. Muss & Thomas C. Shea. (2016) A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. British Journal of Haematology 175:2, pages 281-289.
Crossref
Crossref
Felicitas Hitz, Emanuele Zucca, Thomas Pabst, Natalie Fischer, Anne Cairoli, Panagiotis Samaras, Clemens B. Caspar, Nicolas Mach, Fatime Krasniqi, Adrian Schmidt, Christian Rothermundt, Milica Enoiu, Katrin Eckhardt, Simona Berardi Vilei, Stephanie Rondeau & Ulrich Mey. (2016) Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08. British Journal of Haematology 174:2, pages 255-263.
Crossref
Crossref
V.A. Morrison, P. Hamlin, P. Soubeyran, R. Stauder, P. Wadhwa, M. Aapro & S.M. Lichtman. (2015) Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Annals of Oncology 26:6, pages 1058-1068.
Crossref
Crossref
Christine C. Davis, Jonathon B. Cohen, Katherine S. Shah, Don A. Hutcherson, Minal J. Surati, Kelly Valla, Elyse H. Panjic, Caitlin E. Handler, Jeffrey M. Switchenko & Christopher R. Flowers. (2015) Efficacy and Tolerability of Anthracycline-Based Therapy in Elderly Patients With Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 15:5, pages 270-277.
Crossref
Crossref
Boris Kubuschok, Gerhard Held & Michael Pfreundschuh. 2015. Non-Hodgkin Lymphoma. Non-Hodgkin Lymphoma
271
288
.
Francesca Merchionne, Giovanni Quintana, Francesco Gaudio, Carla Minoia, Giorgina Specchia, Attilio Guarini, Giovanni Quarta, Vincenzo Pavone & Angela Melpignano. (2014) Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis. Leukemia Research 38:12, pages 1446-1450.
Crossref
Crossref
Lidia Gil, Maciej Kazmierczak, Renata Kroll-Balcerzak & Mieczyslaw Komarnicki. (2014) Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. Medical Oncology 31:5.
Crossref
Crossref
Jeffrey L. Vacirca, Peter. I. Acs, Imad A. Tabbara, Peter. J. Rosen, Peter Lee & Eric Lynam. (2013) Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Annals of Hematology 93:3, pages 403-409.
Crossref
Crossref
F. Hitz, N. Fischer, Th. Pabst, C. Caspar, G. Berthod, K. Eckhardt, S. Berardi Vilei, E. Zucca & U. Mey. (2013) Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Annals of Hematology 92:8, pages 1033-1040.
Crossref
Crossref
Zhimin Li, Thomas Caulfield, Yushi Qiu, John A. Copland & Han W. Tun. (2012) Pharmacokinetics of bendamustine in the central nervous system: chemoinformatic screening followed by validation in a murine model. MedChemComm 3:12, pages 1526.
Crossref
Crossref